The Added-value of PSMA PET in Detecting Clinically Significant Prostate Cancer Lesions in Patients Undergoing MRI-targeted Biopsy. (PANDORA)
Launched by JULES BORDET INSTITUTE · Mar 4, 2025
Trial Information
Current as of July 27, 2025
Recruiting
Keywords
ClinConnect Summary
The PANDORA clinical trial is studying how well a special imaging test called PSMA PET/CT can help detect significant prostate cancer lesions in men who have had a recent MRI that showed unclear results. PSMA PET/CT focuses on a protein that is often found in higher amounts in prostate cancer cells, which may allow doctors to better identify cancerous areas that might be missed by traditional imaging methods. This study aims to see if using PSMA PET/CT can improve the accuracy of prostate cancer detection in men who need a biopsy due to uncertain MRI findings.
To participate in this trial, men must be 18 years or older and have had a multiparametric MRI within the past six months that showed at least one lesion classified as PI-RADS 3 (which indicates a moderate suspicion of cancer). Participants will undergo PSMA PET/CT imaging and may then receive a biopsy to confirm any findings. The trial is currently recruiting, so if you or someone you know meets the eligibility criteria, this could be a valuable opportunity to contribute to important research in prostate cancer detection.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- Subjects must meet the following criteria for inclusion in the study:
- • Men ≥ 18 years of age
- • Multiparametric MRI within the previous 6 months
- • At least one lesion PI-RADS 3
- • Able to provide written informed consent
- Exclusion Criteria:
- Eligible subjects must not meet any of the exclusion criteria listed below:
- • Previous prostate cancer diagnostic on MRI-targeted biopsy
- • At least one lesion PI-RADS 4-5
- • Negative MRI (PI-RADS 1-2)
- • Previous treatment for prostate cancer 11
- • Contraindication to PSMA PET and/or MRI and/or prostate biopsy
- • Low quality of MRI defined by a PI-QUAL score of 1 or 2
- • Any medical condition that may interfere with the study procedures.
About Jules Bordet Institute
The Jules Bordet Institute is a prestigious cancer research and treatment center located in Brussels, Belgium, dedicated to advancing oncology through innovative clinical trials and multidisciplinary care. As a leading sponsor of clinical research, the institute focuses on developing novel therapeutic approaches and improving patient outcomes in various cancer types. With a commitment to scientific excellence and collaboration, the Jules Bordet Institute leverages cutting-edge technologies and a robust network of healthcare professionals to foster breakthroughs in cancer treatment and enhance the quality of life for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Brussels, , Belgium
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported